Leerink Partners analysts increased the price target for Genmab A/S (NASDAQ:GMAB) from $29 to $32 and kept an “Outperform” ...

AnaptysBio (ANAB) hosted a webcast to discuss positive rosnilimab Phase 2b rheumatoid arthritis results and featured two leading rheumatologists, ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell ...

Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...

Leerink analyst David Risinger upgraded AbbVie (ABBV) to Outperform from Market Perform with a $206 price target The firm recommends taking advantage of the emraclidine setback and election ...

On Tuesday, Leerink Partners analysts reiterated their Outperform rating and maintained a $65.00 price target for Guardant Health stock (NASDAQ: NASDAQ:GH). This target aligns with the broader ...

On Wednesday, Leerink Partners issued a downgrade for Rocket Pharmaceuticals (NASDAQ: RCKT) stock, moving from an Outperform rating to Market Perform.Accompanying this change, the firm ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to an acquisition by Transcarent. The firm views the ...

Leerink lowered the firm’s price target on Owens & Minor to $14 from $17 and keeps a Market Perform rating on the shares. The firm says the company’s Q3 results had a number of moving pieces ...